MGD management needed for ocular prosthesis wearers

Article

Ocular prosthesis wearers may require clinical assessment and management for meibomian gland dysfunction (MGD).

Ocular prosthesis wearers may require clinical assessment and management for meibomian gland dysfunction (MGD), states the latest paper in the British Journal of Ophthalmology.

A team headed by Dr Jin Sook Yoon, Department of Ophthalmology, Institute of Vision Research, Yonsei University College of Medicine, Korea, assigned a survey to 30 consecutive patients with unilateral ocular prosthesis to identify MGD-related ocular symptoms.

All patients underwent slit lamp examination, meibography imaging and Fourier-domain (FD) optical coherence tomography (OCT) scanning on both eyelids. The main outcome measures were assessed using intra-individual comparison between the eyelids of a prosthetic eye and paired normal eyelids.

Eyelids with ocular prosthesis presented with significantly higher scores for ocular symptoms, lid margin abnormality, meibomian gland expression and meibography compared to normal eyelids.

Tear parameters in the eyelids with prosthetic eyes were significantly lower than normal eyelids. Overall ocular symptom score was significantly positively correlated with meibography score and negatively associated with tear parameters. Clinical evaluation and management recommendations for MGD would highly benefit patients with prosthetic eyes, especially those demonstrating ocular discomfort.

Please click here to read the abstract.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.